Bundled payment for ESRD - Including ESAs in medicare's dialysis package

New England Journal of Medicine

Volumn 364, Issue 7, 2011, Pages 593-595

  Iglehart, John K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ERYTHROPOIETIN; IRON; VITAMIN D;

DIALYSIS; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE QUALITY; HEALTH PROGRAM; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MEDICARE; PRIORITY JOURNAL; SHORT SURVEY; SOCIAL SECURITY;

EID: 79951839142     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1014187     Document Type: Short Survey

References (5)

1. Medicare program; end-stage renal disease prospective payment system: final rule. August 12, 2010. Fed Regist 2010;75:49029-214. (http://edocket. access.gpo.gov/2010/pdf/2010-18466.pdf.)
2. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90. (Pubitemid 28385655)
3. Report to Congress: Medicare payment policy. Washington, DC: Medicare Payment Advisory Commission, 2001.
4. Fields R. In dialysis, life-saving care at great risk and cost. ProPublica. November 9, 2010. (http://www.propublica.org/article/in-dialysis- life-saving-care-at-great-risk-andcost.)
5. Zhang Y, Cotter DJ, Thamer M. The effect of dialysis chains on mortality among patients receiving hemodialysis. Health Serv Res. December 9, 2010. DOI: 10.1111/j.1475-6773.2010.01219.x.